Most clients of Argus Research are long-term buy-and-hold investors. As such, our proprietary BUY-HOLD-SELL ratings and target prices are established with one-year time horizons. We also have five-year ratings for longer-term investors and pension fund managers. But we do have select momentum-driven hedge fund clients who are looking more for trading opportunities or for long/short portfolio picks. The list below includes some of the shorter-term trading ideas our analysts and strategists recently identified for this cohort of clients. All of these stocks are rated BUY at Argus.

The S&P 500, Dow Jones Industrial Average, and Nasdaq Composite are trying to stay above water at midday on Friday, this as a losing week for stocks comes to an end. As of this writing, the three majors are between 0.36% higher and 0.20% lower, as new catalysts for higher prices are hard to find and ongoing worries about an AI bubble and the future of interest rates remain firmly in the mindset of many investors.

Vertex Pharmaceuticals develops therapies to address cystic fibrosis and other diseases. The company was founded in 1989 in Cambridge, Massachusetts and has 6,100 employees. It has research programs and facilities in the U.S., the U.K., and Canada. The shares are a component of the S&P 500.

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.